Q-omics provides the consensus-scored MTNR1B profile across patient tissues and cancer cell-line models. MTNR1B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MTNR1B is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, MTNR1B RNA expression shows 9,356 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, UCEC, and TGCT as cancer lineages where MTNR1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTNR1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTNR1B survival associations across molecular data types. MTNR1B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTNR1B RNA expression–survival associations across cancer types. High MTNR1B expression shows unfavorable associations in KIRC, LIHC, BRCA, UCEC and DLBC, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRC as the clearest survival context for MTNR1B RNA expression.
This table summarizes MTNR1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for MTNR1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTNR1B shows higher tumor expression in UCEC, LIHC, BLCA and LUAD. The UCEC box plot shows higher MTNR1B RNA expression in tumor versus normal tissue (log2 FC = +0.139, t-test p = .012).
This table shows molecular features associated with MTNR1B in patient tissues and cancer cell lines. In patient samples, MTNR1B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MTNR1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and STOMACH.
